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Sonochemical Formation of Copper/Iron-modified Graphene 
Oxide Nanocomposites for Ketorolac Delivery 
Darya Radziuk,*[a] Lubov Mikhnavets,[a] Mykhailo Vorokhta,[b] Vladimír Matolín,[b] Ludmila Tabulina[a], 
and Vladimir Labunov[a]  
 
Abstract: A feasible sonochemical approach is described for the 
preparation of copper/iron-modified graphene oxide nanocomposites 
by using ultrasound (20 kHz, 18 W/cm2) in aqueous solution 
containing copper and iron ion precursors. Unique copper-, 
copper/iron- and iron-modified graphene oxide nanocomposites 
have a submicron size that is smaller than pristine GO and a higher 
surface area enriched with Cu2O, CuO, Fe2O3 of multiform phases 
(α-, β-, ε- or γ), FeO(OH) and sulfur- or carbon-containing 
compounds. These nanocomposites are sonochemically intercalated 
with the nonsteroidal anti-inflammatory drug ketorolac resulting in 
formation of nanoscale carriers. Ketorolac monotonically 
disintegrates from these nanoscale carriers in aqueous solution 
adjusted to pH from 1 to 8. The disintegration of ketorolac proceeds 
at a slower rate from the copper/iron-modified graphene oxide at 
increased pH, but at a faster rate from the iron-modified graphene 
oxide starting from acidic conditions.   
Introduction 
Nonsteroidal anti-inflammatory drugs (NSAIDs) are among the 
most commonly prescribed medications worldwide to treat the 
inflammation and pain, thereby reducing fever and inhibiting the 
thrombocyte aggregation.[1]  Among many NSAIDs ketorolac is 
related to the type of pyrroles being most potent and effective 
analgesic to be used after surgery with efficacy comparable to 
opioids.[2] Ketorolac’s pyrrolizidine carboxylic acid derivative is 
structurally related to indomethacin acting as cyclooxygenase-2 
(COX-2) inhibitor. Recently ketorolac demonstrated down 
regulation of the expression of regulatory subunit of Casein 
Kinase 1 in Wnt–β-Catenin Signaling, i.e. DDX3, being involved 
in the progression of several types of cancer.[3] The anticancer 
activity of ketorolac can be associated with its free binding 
energy being closer to DDX3 inhibitors, its capability to form 
strong hydrogen bonds similar to crystallized DDX3 protein and 
to inhibit the ATP hydrolysis decreasing the number of 
neoplastic lesions. Ketorolac also suppresses early breast 
cancer relapse and improves its postoperative oncological 
outcome.[4] Ketorolac’s anticancer effects and its aptitude to 
deactivate inflammatory pathways can be particularly useful in 
retardation of tumor growth.[5]  
Commonly ketorolac is administered as the tromethamine 
salt orally, intramuscularly, intravenously, or as a topical 
ophthalmic solution. It is considered a first-generation NSAID 
with the efficacy being 800 times higher than aspirin and 
biological half-life of 4-6 h.[6] Ketorolac is non-addictive in nature 
and does not induce nausea and respiratory side effects. 
However, in its most frequent form, i.e. the oral tablet, the drug 
is delivered to the human body through the gastro-intestinal 
system, which undergoes bleeding and develops gastritis after 
repeated doses over prolonged administration.[7] In addition, its 
ability to selectively inhibit COX2 has important cardiovascular 
side-effects that include increased risk for myocardial infarction, 
stroke, heart failure and hypertension.[8] For human health 
benefits one has to consider appropriate approaches for the 
administration of ketorolac at a lower dose over shorter period of 
the systemic exposure while maintaining its therapeutic 
efficacy.[9]  
Nanomedicine offers beneficial approaches based on 
objects at the nanoscale aiming at an increase of the drug 
surface area by reducing its size and modifying its surface to 
facilitate more rapid dissolution and absorption by a target 
tissue.[10-17] Moreover, it provides techniques for safe handling 
and methods for minimizing toxicity of nanoscale carriers for the 
in vivo application.[18-21] These nanoscale carriers can 
significantly improve the bioavailability of drug and decrease the 
dose of administration, thereby enhancing its therapeutic 
efficacy with lower side effects. The anti-inflammatory activity of 
NSAIDs can be enhanced through the formation of Cu(II)-
complexes with drugs functionalized with the carboxylate group 
operating as a bridging ligand involving Cu-O and Cu-Cu bonds 
in the complexes undertaking the enzyme superoxide dismutase 
(SOD).[18] In addition, the CuO derivatives have a high oxygen 
radical scavenger activity and the peripheral parts of the 
complex molecules are mostly hydrophobic in character.[22] 
These neutral binuclear molecules with a high peripheral 
hydrophobicity can exert a SOD-like activity once the apical 
positions on Cu(II) are made free, which can be useful in the 
understanding of the drug-metal and drug-enzyme interactions. 
Importantly, the copper carboxylates drugs constitute an 
important element of anti-inflammatory and anticancer agents, 
some of which are a part of several commercially available 
drugs.[23]  
The complexation of NSAIDs with other metals such as 
Cd (II), Pt (II), Fe (II), Ni (II) or Zn (II)[24,25] leads to the 
scavenging of free radicals (incl. oxygen) and results in 
enhanced gastric protection.[26] This improved pharmacological 
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activity of metal complexes of active drugs as ligands can derive 
from the synergistic effects of the ligand and the coordination 
residue upon the decomposition of the molecular metal-NSAID 
complex or an intrinsic high activity of the complex itself, the 
neutralization of overall negative charges on the drug molecule 
upon the complex formation, superior transport process through 
the cell membranes due to the changes of the 
hydrophobicity/hydrophilicity ratio. The anti-inflammatory, anti-
pyretic and analgesic activity of drug can be improved through 
the formation of the Fe(III)-peptide complex yielding the ligand 
moieties containing oxamide functionality.[27] Other studies show 
the antibacterial efficiency of some Fe(III)-NSAID complexes: i) 
the Fe(III)-paracetamol complexes can enhance the inhibitory 
effect against E. coli[28] and ii) the Fe(III)-lornoxicam (LOR) 
complex can inhibit the bacterial growth capacity for the 
Staphylococcus aureus due to the ability of the complex to cross 
a cell membrane and inactivate the pathogens secreting various 
enzymes, which are involved in the breakdown of activities.[29] 
Importantly, the Fe(III)-complex can facilitate the ion diffusion 
through the lipid layer of the spore membrane to the site of 
action and ultimately kill them by combining with the OH, SO2 
and C=N groups of certain cell enzymes. On the other hand, the 
metal complex of Fe(II) can be very active against breast cancer 
cell line (MCF7) with inhibition ratio values between 74-86 %. 
Other approaches in minimizing dosage can be based on 
NSAID encapsulation, which utilize a nanoscale carrier that 
transports the active drug ingredient and facilitates controlled 
release at the therapeutic target site.[30-32] This strategy can 
overcome issues with the drug solubility, prevent degradation in 
the gastrointestinal system, improve the bioavailability at the 
therapeutic site, and reduce the systemic exposure. Still a major 
obstacle of the encapsulation approach is the uptake of 
nanoscale carriers by macrophages and subsequent clearance 
of the drug.[33,34]  
Graphene oxide (GO) can be used as a nanoscale carrier 
for a drug due to its high surface area, biocompatibility and a 
very rich surface chemistry offering a wide choice for the smart 
design of effective drug delivery platform.[35-39] GO can remain 
for a long time in a body and have good biocompatibility, but 
size, shape, agglomeration state and toxicity (presence of 
contaminants) can cause undesired inflammation.[33,40] GO 
biodegradation can be modulated by dispersion and digestion by 
peroxidases naturally present in cells. Appropriate GO 
purification and modification can increase the efficacy of drug 
loading in GO and optimize adsorption/desorption kinetics at 
minimal toxicity.[41-44] The rich GO surface chemistry facilitates 
functionalization with diverse molecular compounds: dyes,[45] 
inorganic[45-48] and organic (DNA,[49] ssRNA,[50] gene[51]) 
substances, polymers,[52-55] luminescent or fluorescent 
particles[56,57] enabling synergistic effect of drug delivery and 
bioimaging[58-61] of a carrier platform. Immobilization with drug 
molecules can regulate the GO dispersal in water or in the cell 
culture media, reduce its cell/tissue toxicity and induce 
accumulation to the target cells and tissues.[62-65] Drug release 
from GO can be activated by the pH gradient naturally present in 
the cells/tissues through the distortion of the interactions 
between the drug and GO nanocomposite.[53]  
Sonochemistry is an efficient tool to construct multifarious 
molecular carriers for resourceful drug delivery,[66] and it derives 
from acoustic cavitation, which is the formation, growth and 
implosive collapse of gaseous bubbles, acting as highly 
energetic hot spots.[67] These hot spots can reach 5000 K and 
103 bar in a bulk aqueous solution producing sonolysis of 
water.[68] Sonolysis of water generates OH· and H· radicals and 
the primary products such as H2, H2O2 and HO2· performing 
redox reactions.[69] Sonochemistry is being actively involved in 
the molecular assembly and encapsulation processes through 
the cross-linking mechanisms (disulfide bond formation) in 
proteins[70] that retain their biological function. In many cases 
superoxide (HO2·) is the principal cross-linking agent.[69,71] To 
date, this sonochemical pathway has been very successful in 
the encapsulation of antibiotic nanoparticles in GO[62] that is 
immaculate or modified with Ag,[72] Fe3O4,[73] Au[74] and their 
bimetallic compounds.[75] Nowadays little is known about the 
sonochemical formation mechanism of hybrid copper/iron GO 
nanocomposites and much less about the NSAID intercalation 
into their structure.  
For the first time, we introduce a convenient sonochemical 
method for the preparation of a hybrid copper/iron-modified GO 
nanocomposite and reveal its formation mechanism. The 
complexation of the ketorolac with copper, copper/iron or iron 
can be useful in the understanding of the drug-metal or drug-
metal oxide interaction for the fundamental studies of the drug-
enzyme reactions, of the crossing the cell membrane and 
activation of the breakdown activities. Here we also report on the 
sonochemical intercalation of ketorolac into this unique material 
and disclose its degradation in aqueous solution being adjusted 
to a pH from 1 to 8. The pH values were chosen for the reason 
of comparison with the cellular media of human gastric juice in 
stomach (~ 1.5-3.7),[76] lysosomes (~ 4.3-5.3),[77] urine (~ 5.9-
6.7),[78] duodenum (~ 6.0-8.0),[79] and pancreas or insulin 
secretion (~ 5.0-10.5).[80]  
Results and Discussion 
The successful GO formation (sample N1) was confirmed 
through the characterization of its physico-chemical properties 
by using X-ray powder diffraction, Raman microscopy and 
thermogravimetric analysis (Figure S1, see more details in the 
supporting information). These synthesized GO were 
sonochemically modified with copper and iron compounds at the 
first step and the sonochemical intercalation of the anti-
inflammatory drug ketorolac into their structure at the second 
step (Scheme 1).  
 
 
Scheme 1. Schematic illustration of the sonochemical modification of 
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iron compounds at the first step, and subsequent ultrasonic intercalation 
(20 kHz, 18 W/cm2, 3 min, horn-type ultrasonic disperser) of the copper/iron-
modified@GO nanocomposite by ketorolac (NSAID drug) in aqueous solution.  
 
Ultrasound with a horn type (20 kHz, 18 W/cm2) was used 
to prepare copper- (sample N2), copper/iron- (sample N7) and 
iron@GO nanocomposites (sample N9) in aqueous solutions 
containing Cu2+ and Fe3+ ion precursors. Figure 1A 
demonstrates synthesized GO before the sonochemical surface 
modification, showing nanomaterial with a size distribution 
~ 500 nm (relative standard deviation, r.s.d. ≈ 25%) (Figure S1A).  
 
 
Figure 1. Representative SEM images of (a) synthesized graphene oxide 
(GO) and sonochemically prepared nanocomposites: (b) copper@GO 
(sample N2), (c) copper/iron@GO (sample N7) and (d) iron@GO (sample N9).  
 
SEM image of N2 nanocomposite reveals GO with a 
decorated spherical morphology (Figure 1B), which changes 
into elongated nanostructure in the shape of a grain rice of 
smaller size in sample N7 (~ 580 nm, r.s.d. ≈ 16%) (Figure 1C) 
and of larger size in sample N9 (~ 460 nm, r.s.d. ≈ 3%) 
(Figure 1D). These sonochemically formed morphologies are 
clearly distinct from nanoparticles that were ultrasonically grown 
on the external walls of sonicated multi-walled carbon nanotubes 
functionalized with the carboxylic acid groups, i.e. fCA-MWCNTs, 
from our previous studies.[81] In contrast to graphene oxide 
nanocomposites, those erbium carboxioxide nanoparticles 
appeared with the nonuniform geometry and a broad diameter 
distribution from 50 to 200 nm, the size being comparable to the 
highly fluorescent polymeric nanoparticles that exhibit the 4.5-
fold increase in the quantum efficiency, when compared with the 
free dye molecules in water.[82] Importantly, the presence of GO 
leads to the growth of nanoparticles with a more pronounced 
morphology that has a spherical or elongated rice-like shape 
than carbon nanotubes being used as a template material. On 
the other hand, ultrasonic treatment with the carbon nanotubes 
yields smaller nanoparticles than those with GO. We assume 
that GO provides a larger surface area enriched with higher 
amount of oxygen containing chemical groups than carbon 
nanotubes resulting in the enhanced nanoparticle’s growth with 
a more defined morphology.  
Volume composition of copper/iron-modified@GO 
nanocomposites 
In Figure 2 the phase composition of synthesized GO 
before and after sonochemical surface modification with copper 
and iron compounds was revealed by the X-ray powder 
diffraction analysis in accordance with the XRD database 




Figure 2. X-Ray powder diffraction patterns of (a) synthesized GO 
(sample N1, black line) and sonochemically prepared nanocomposites: 
copper/iron@GO (sample N7, wine line), iron@GO (sample N9, violet line) 
and (b) copper@GO (sample N2, orange line). (a) Circles of orange color 
indicate Cu2S (046) at 2θ=46.5 and (12 4 2) at 47.9. (b) The crystalline phases 
in N2 nanocomposite are indicated by black arrows as following (001) at 
2θ=14.5 of Cu(HOOC); (101) at 27.6, (102) at 29.2, (103) at 31.9 of CuS; 
(002) at 34.9, (111) at 38.4, (200) at 40.0 of CuO, (200) of Cu2O (at 42.1), 
(108) at 52.8(200) at 55.1 and (116) at 59.0 of CuS; and (-113) at 62.7 of CuO 
according to the databases in the Table S1. Red arrows indicate strong peak 
at 2θ=46.4 being assigned to the (-112) plane of CuO considering its shift from 
2θ=48.8.  
 
XRD pattern shows the GO phase due to the presence of a 
characteristic peak at 2θ=11.9 arising from (001) plane, more 
details in supporting information (Figure S1B). The phase 
composition of N7 nanocomposite is dwelled in the successful 
formation of cuprite Cu2O with characteristic reflections (110) 
and (111); tenorite CuO with the plane (202); hematite α-Fe2O3 
with (104), (110), (006), (113) and (214) planes; maghemite γ-
Fe2O3 with (422) plane; ε-Fe2O3 with (120) plane; recently 
discovered Fe4O5[83] with (002) plane; covellite CuS with (203) 
and (110) planes; Cu2S with (332), (046) and (12 4 2) planes, 
and GO with (001) plane (Figure 2A). In this nanocomposite the 
XRD (001) plane of GO is very weak, indicating large range 
atomic coherence. The relatively larger d-spacing of GO may 
also indicate the formation of oxygen-containing functional 
groups in metal oxides in the sonochemically modified GO.[84] 
Most prominent peaks arise from (111) Cu(HCOO), (111) Cu2O, 
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nanocomposite indeed contains copper and iron oxides as well 
as copper sulfide.  
The elemental composition of N7 nanocomposite was 
obtained from the EDX spectra (Table 1). N7 nanocomposite is 
composed of C (35.6 atom.%), O (44.5 atom.%), Cu 
(1.7 atom.%), Fe (13.8 atom.%) and S (2.6 atom.%), in 
agreement with the XRD analysis (Figure 2A). In contrast, N1 
contains only higher amount of C (58.7 atom.%), but lower 
concentration of O (39.5 atom.%). The amount of sulfur in N1 is 
twice less than in N7 nanocomposite. We attribute these 
changes in the elemental composition to the ultrasonic effects 
on the GO nanostructure (e.g. defect formation and intercalation 
of S in the carbon lattice)[85] and to the sonochemical redox 
reactions between copper, iron, sulfur (acting as reductant) and 
radical species, i.e. hydrogen (reductant); hydrogen peroxide, 
hydroxyl and oxygen acting as oxidants.[69] 
The dominant (111) XRD peak of Cu2O is relatively sharp, 
demonstrating the presence of a material larger than 5 nm in N7 
(Figure 2). Very small (110) peak of Cu2O may result from 
nanocrystal partial reduction post synthesis involving diffusion of 
atoms and lattice expansion process, which may be limited to 
atom rearrangement and lattice/unit cell reconstruction yielding 
rich Cu2O phase (i.e. copper in oxidized state). We assume that 
complete transformation of Cu2O to crystalline CuO does not 
occur because of the following possible reasons: i) 
sonochemical reactions involving reductants such as Na2S and 
radicals (i.e. H2·) and oxidants (i.e. OH·, H2O2·, HO2·); ii) there is 
a considerable energetic difference between the Pn3 group of 
Cu2O and monoclinic C2/c group of CuO structure; iii) Cu2O has 
the high-symmetry cubic and CuO has a low-symmetry 
monoclinic structure; iv) there may be possible stabilization of 
the (I) oxidation state by the carbon network of GO and the 
present Fe3+ ions. This carbon network of GO can be 
ultrasonically doped by S2- due the presence of Na2S resulting in 
the formation of reduced S-GO nanostructure, and later CuS 
synthesis through the sonochemical reduction of Cu(II).[86] 
Indeed, XRD reveals CuS, Cu2O and CuO phases in N2 
nanocomposite, indicating that Cu(I) phase may be stabilized by 
the carbon lattice network of GO containing intercalated sulfur 
as a result of interaction with the sonochemically produced 
radicals, Cu2+ and S2- ions (Figure 2B).  
Three crystal structures of Fe2O3: γ-ε-α as well as rare 
Fe4O5 phase were revealed in N7 nanocomposite, showing that 
the phase transformation may take place depending on the 
particle size, temperature or pressure during the sonochemical 
synthesis.[86-88] Most of these XRD peaks are relatively small, but 
not significantly broadened, denoting the formation of 
nanoparticles smaller than submicron size, in agreement with 
the SEM in Figure 1B. The XRD pattern reveals α-Fe2O3 
(≈ 80%) as the main phase along with γ-Fe2O3 (≈ 10%), ε-Fe2O3 
(≈ 7%) and Fe4O5 (≈ 3%). In this iron oxide polymorph structure 
the most thermodynamically stable form is α-Fe2O3. Other 
metastable polymorphs can be stabilized during the decrease of 
the iron oxide crystallite size.[88] Another parameter is the 
reaction temperature: at 530°C all these polymorphs can be 
formed, while heating to 650°C may lead to the disappearance 
of γ-Fe2O3 and ε-Fe2O3 phases, and leaving α-Fe2O3 at 700°C. 
Such high temperatures can arise during the acoustic cavitation, 
which forms highly energetic hot spots upon the bubble collapse 
(T ≈ 5000 K and P ≈ 103 atm) in the bulk solution.[68] The 
existence of these conditions is confirmed by the presence of a 
high-pressure and high-temperature polymorph of iron oxide 
Fe4O5, which is stable from 5 to at least 30 GPa.[83] Fe4O5 can 
be readily synthesized at 10 and 20 GPa, upon heating at 1500-
2200 K. This recently discovered phase can result from the 
breakdown of magnetite into Fe4O5 and Fe2O3. The magnetite 
can be also formed as a result of transformation of γ-Fe2O3 
under 600 K[89] and due to the sonochemical reduction of Fe3+.[90] 
There is no β-Fe2O3 in our nanocomposites, which can be a 
result of longer thermal treatment during sonication, indicating 
the existence of independent transition chain γ-Fe2O3 → ε-Fe2O3 
→ α-Fe2O3. Other factors such as increase of the α-Fe2O3 
particle size may contribute to the formation of the β 
polymorph.[91]  
 
XRD discloses (001) plane of GO and the following phases 
(110), (006) and (214) α-Fe2O3; (120) and (330) ε-Fe2O3; (440) 
β-Fe2O3, (100) and (210) FeS along with (100) graphene in N9 
nanocomposite (Figure 2A and Table S1). In contrast to N7, in 
XRD pattern of N9 the (100) plane of GO disappears and (001) 
plane of GO appears as intense and broad reflection, indicating 
the layered structure of nanocomposite with a very short range 
atomic coherence. Strong XRD (001) peak is characteristic of 
GO because it shows oxygen containing functional groups on 
carbon sheets. To note, the γ-Fe2O3 phase was not revealed in 
XRD pattern. The presence of polymorph metastable ε-Fe2O3 
and β-Fe2O3 phases, which exhibit relative intensity comparable 
to that of the α-Fe2O3 phase may result from high 
heating/cooling rates (i.e. > 107 K/s) during acoustic cavitation, 
which can lead to the partial or complete amorphization or 
recrystallization of material.[92] The layered structure of GO 
doped by Fe3+ ions may act as a buffer against transition to the 
α-Fe2O3 phase in aqueous solution. The existence of the 
transition chain ε-Fe2O3 → α-Fe2O3 without γ-Fe2O3 shows 
effects of high temperature during the sonochemical synthesis. 
Typically ε-Fe2O3 is an intermediate polymorph between γ-Fe2O3 
and α-Fe2O3. The formation of the γ-Fe2O3 phase requires the 
presence of Fe3O4 at 300°C, but XRD does not reveal this phase 
in material[93] because of the absence of Fe4O5.[83] On the other 
hand, there is a FeS phase, which is a very stable crystalline 
phase even at 800°C and under pressure of up to several GPa. 
We assume that FeS may be formed according to the 
mechanism similar to copper sulfide, in agreement with our 
recent work.[55] In this way, the difference in the composition 
between copper- and iron-modified@GO nanocomposites may 
be attributed to the characteristic electrochemical potential of Cu 
(0.153 J/mol) and Fe (-0.037 J/mol), implying that more energy 
may be required for the reduction of Fe3+.   
Surface chemical composition of copper/iron-
modified@GO nanocomposites  
Figure 3 parts A and B show the surface chemical 
composition and bonding of synthesized GO (N1) and 
sonochemically prepared nanocomposites (N2, N7 and N9). In 
Figure 3A N1 is mainly composed of C and oxygen containing 
surface groups (C/O = 1.7 atomic ratio, Table 2) and a small 
Table 1. Elemental composition of synthesized GO (sample N1) and 
sonochemically prepared copper@GO (sample N2), copper/iron@GO 














N1 58.7 39.5 - - 1.3 - 
N2 33.4 18.2 28.1 - 17.8 - 
N7 35.6 44.5 1.7 13.8 2.6 - 
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amount of S (0.6 atom.%). The surface groups are the following: 
carbonyl (R-C=O-R'), epoxide (R-C-O-C-R') and carboxyl 
(C(=O)OH).[94]  
We assume that the carbon lattice is not intercalated by S 
(high C/S ratio ~ 105) and sulfur undergoes oxidation during 
ultrasonic dispersion of GO in the aqueous solution. Sulfur has 
several oxidation states and tends to stabilize into SO4 (O/S 
~ 62). The lower energy C1s line at ~ 284.5 eV (C-C bond in all 
samples) is assumed to be rather generic aliphatic than graphitic 
carbon (~ 284.0 eV).[95] Another C1s component at ~ 286.7 eV 
(in all samples) is attributed to the π-π* shake-up bands of the 
highly aromatic 18π electron system and can be assigned to the 
C-O bond. The OH group may also present in the GO structure 
because its C 1s binding energy is similar to the epoxide group 
(C-O-C).[96] The lower energy C1s line is indicative for the sp2-
hybridized graphite consisting of the hexagonal network of 
parallel carbon layers with covalent bonding between C-C atoms 
within a plane. The higher energy C1s component is attributed to 
the sp3-hybridized carbon atoms with a typical diamond 
structure. Overall, the ratio of all samples is higher with the sp3 
hybridized carbon chemical state that is related to a diamond 
structure with a C-C bond length ~ 0.15 nm. 
 
 
Figure 3. Representative XPS spectra of synthesized GO (sample N1), 
copper@GO (sample N2), copper/iron@GO (sample N7), and iron@GO 
(sample N9) nanocomposites: (A) XPS C 1s and (B) O 1s. The curve fitting of 
the C1s (A) and O1s (B) spectrum was performed using a Gaussian-
Lorentzian peak shape after performing a Shirley background correction. The 
color coding represents raw spectra (black) and their fits (red), and fitted peak 
components are presented in other colors.  
 
To note, the sp2-hybridization is related to the graphite, 
which consists of parallel carbon layers. The C1s component at 
~ 288.4 eV (present in all samples) is indicative for the oxidized 
surface containing higher amount of oxygen. 
From the C/O atomic ratio we assume that N7 is composed 
of excess of oxygen and oxygen-containing compounds (C/O ~ 
0.3) involving both copper and iron, and a much lower amount of 
carbon (Table 2). In N9 and N2 the amount of carbon is twice 
higher than oxygen (C/O ~ 2.4 and 2.1), but the surface 
enrichment with copper or iron oxides is comparable (O/Cu ~ 8 
and O/Fe ~ 6). The increasing loss of oxygen could be 
associated with the oxygen-deficient regions (i.e. vacancies)[97,98] 
and the S ion doping effect. In contrast to N1, the binding energy 
of the C-C band in each type of nanocomposite shows another 
component at higher values ~ 285 eV (aromatic carbon), 
indicating that the separation between C and other atoms 
decreases. The binding energy of this second C-C component is 
systematically shifted by ~ 0.1 eV to the lower values being at ~ 
285.5 eV (in N2), ~ 285.4 eV (in N7) and ~ 285.3 eV (in N9). In 
general the peak at 285 eV corresponds to the C-O or C-S 
suggesting that S ion can be intercalated into the carbon 
lattice.[85] To note, in N2 and N9 a small broad C1s component 
peak at ~ 290.5 eV discloses copper or iron carbonaceous 
compounds or their sulfides bound to the carbonyl groups of 
GO.[99] We will prove later in the text that this peak cannot be 
assigned to the presence of CuCO3, FeCO3 or iron-hydroxyl 
carbonate Fe(OH)2CO3.  
In Figure 3B the XPS O1s line is introduced by two 
components in N1: main peak at ~ 532.6 eV (C-O/C=O) and 
minor peak at ~ 531.6 eV (SO4). In N7 the O1s line is composed 
of four components being assigned to Fe2O3 and Cu2O 
(530.2 eV), SO4 (531.5 eV), C-O/C=O (532.5 eV) and OH 
(533.7 eV). We assume that the surface of N7 is more enriched 
with oxygen (C/O ~ 0.3) and sulfur (C/S ~ 5) than in N2 or N9, in 
contrast to N1 (Table 2). The N7 nanocomposite contains more 
iron than copper (Fe/Cu ~ 20), which is bound to sulfur (S/Fe 
~ 0.1) and oxygen (O/Fe ~ 2), implying the presence of FeS (i.e. 
Fe2+S2-) and FeOOH compounds. We suggest that N7 may also 
contain Cu+Fe3+S2 and Cu+Fe2+Fe3+S3 because S/Cu ~ 2.6 
(Table 2). We assume the presence of Cu-CO(O) and CuO in 
N7 (O/Cu ~ 46 and C/Cu ~ 13). For comparison, N2 can contain 
CuS (S/Cu ~ 1) and CuO (O/Cu ~ 8). The carbon lattice is 
intercalated with a greater amount of sulfur in N2 than in N9 
(C/S ~ 16 and ~ 72).  
 
 
We ascertain that in N9 iron hydroxides and oxides such as 
Fe3+O2-(OH)-, Fe2+(OH)2-, Fe3+(OH)3-, Fe2O3 and Fe2+O2- may be 
also present. In N2 and N9 XPS spectra confess the 
appearance of Na KLL Auger lines at 534-541 eV that overlap 
with O1s, suggesting the presence of NaOH and Na2SO4. In N9 
FeS with Fe2+ and S2- oxidation states and SO4 can be formed. 
We expect that the presence of negligible amount of sodium 
compounds in both N2 and N9 may be also contributed by the 
acoustic cavitation impact on the glass walls of a reaction vessel 
due to diffusion processes,[100,101] in addition to the sonochemical 
reactions involving Na2S and radical species.  
The XPS Cu2p lines reveal main component peaks for the 
Cu+ (designated as Cu (I)) in N2 and N7, proving the formation 
of Cu+S-, Cu2+S2- and Cu2+O2- (Figure S2A). The existence of 
Table 2. The values of atomic concentration (atom.%) estimated from peak 
areas corrected by the sensitivity factor (SF) for the chemical bonds derived 
from the XPS spectral lines of synthesized GO (sample N1), copper@GO 
(sample N2), copper/iron@GO (sample N7) and iron@GO (sample N9).  
Atom.% C O S Fe Cu Na Ca Cl 
N1 62.8 36.7 0.6 - - - - - 
N2 61.3 29.2 3.8 - 3.8 1.4 0.6 - 
N7 15.7 55.2 3.1 24.2 1.2 - - 0.7 
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the Cu+ state in N2 and N7 was also confirmed by the Cu LMM 
Auger line at ~ 918 eV (Figure S2B). We do not exclude the 
possible formation of metallic copper because its binding energy 
value is at ~ 933 eV and ~ 952.75 eV.[102] We suggest that no 
CuCO3 or Cu(OH)2 are produced because their binding energies 
for the Cu2p3/2 and Cu2p1/2 lie at higher values, i.e. 935 eV and 
955 eV for the first compound, and 937 eV and 957 eV for the 
second compound. To note, the appearance of CuCO3 is 
associated with the C1s peak at 287.5 eV and O1s at 533.9 eV, 
which are not observed in either N2 or N7. In addition, we 
exclude the formation of CuSO4 and Cu3(SO4)(OH)4 because the 
XPS Cu2p also have higher binding energy values (935.2 eV 
and 955.0 eV).[99] To note, small broad peak at 934.8 eV and 
shake-up components at 943.5 eV and 963.8 eV appear only in 
N2, disclosing the Cu2+ state,[99,102,103] which can be attributed to 
the formation of Cu2+S2 and Cu2+O2-.[104-107] High temperature 
(~ 800°C) may lead to the appearance of Cu2O preventing CuO 
formation.[108] On the other hand, the reduction of CuO to Cu2O 
may be expected from the decomposition to Cu2O at > 
1073°C.[109] Such high temperature can be created by hot spots 
during acoustic cavitation.[110] 
The XPS Fe2p line reveals a doublet at ~ 711.6 eV and ~ 
725.6 eV in both N7 and N9, denoting hydrated iron oxide[111] or 
ferric oxidation products (Figure S2C).[112] This doublet may be 
indicative for Fe2+O2-, hematite α-Fe2O3 (~ 711.4 eV), γ-Fe2O3 
(~ 711.8 eV), hydroxyl-oxide FeO(OH) that may have an 
intermediate composition between goethite α-FeOOH (711.8 eV) 
and α-Fe2O3.[113] Small satellite peaks (at ~ 719.8 eV and 
~ 733.2 eV) appear only in N7, designating for Fe3+ in FeO(OH) 
and Fe2O3. It is important to note, that magnetite (i.e. Fe3O4) 
compound is not detected on the surface of neither N7nor N9, in 
agreement with the XRD bulk material analysis (Figure 2). 
Usually the formation of magnetite requires low temperature 
(< 100°C) and reducing conditions, meaning low or no-oxygen 
environment. The presence of the sulfate ion may lead first to 
the formation of iron oxyhydroxysalts followed by transformation 
into goethite,[114] which is a product of pyrite oxidation.[115] Pyrite 
oxidizes to produce S and SO4, and the formation of S is 
restricted to the order of a monolayer in basic aqueous solution. 
Products of pyrite dissolution in alkaline medium are hematite α-
Fe2O3 and ferrihydrite. We suggest that hematite is present in 
both N7 and N9, whilst ferrihydrite can be produced only in N9 
because of the higher O/Fe ratio (~ 6 in N9 and ~ 2 in N7). 
Reduction of iron hydroxide in the presence of S leads to the 
formation of iron sulfide. We assume that iron hydroxide can be 
formed on the pyrite surface in N9 because of stronger OH peak 
relatively to O in Figure 3B.  
We suggest that SO4 ions are adsorbed by Fe2O3 via the 
replacement of two OH groups by forming a bridge bond Fe-O-
S.[116] The formation of FeCO3 and Fe(OH)2CO3 may be 
excluded because of the lower binding energy values, i.e. ~ 
710.2 eV (Fe2p3/2) and ~ 723.7 eV (Fe2p1/2). We also may 
exclude the presence of metallic iron because its binding energy 
value lies at ~ 706.7 eV (Fe2p3/2) and ~ 720.3 eV (Fe2p1/2). The 
presence of FeS and FeSO4 (also Fe2(SO4)3) on the surface of 
N7 is less probable (~ 712.2 eV and ~ 712.1 eV), but not in N9, 
where there may be a small contribution of both these 
substances as a result of a broadened peak at 711.6 eV. To 
note, the XRD analysis of N9 bulk material reveals the FeS 
phase (Figure 2), pointing out that iron sulfate may be 
exclusively located on the surface. The reason why FeS is not 
detected either in the bulk or on the surface of N7 may be 
explained by the reaction of iron with copper resulting in binary 
Cu+Fe3+S2 and Cu+Fe2+Fe3+S3 compounds. The presence of 
sulfates is confirmed by the appearance of a relatively broad 
XPS S2p doublet at 168-171 eV in N1 and each nanocomposite 
(Figure S3).[96,99] In N7 the XPS line at ~ 162-164 eV is broad 
and small, and may be attributed to the doublet for the Cu+S- 
(162.0 eV), Cu2+S2- (162.4 eV) and Fe2+S2- (162.9 eV). In N2 
Cu2+S2- (161.2 eV) and Cu2+S2- (162.06 eV) can be present, 
while in N9 a broad peak may be attributed to Fe2+S2- 
(162.9 eV).  
Sonochemical formation mechanism of copper/iron-
modified@GO nanocomposites 
Let us refer to the sonochemical synthesis in order to 
understand the formation mechanism of prepared 
nanocomposites. This sonochemical synthesis is conducted in 
three successive steps: 1) ultrasonic treatment of the 
synthesized GO with Na2S acting as a strong reductant; 2) 
sonication of previously treated GO in aqueous solution 
containing Cu2+ and Fe3+ ion precursors; 3) ultrasonic treatment 
of the sonochemically preformed copper or iron - modified GO 
with Na2S.  
In the first step water undergoes sonolysis, producing 
hydrogen and hydroxyl free radicals (H· and OH·) and their 
recombination products such as molecular hydrogen (H2) and 
hydrogen peroxide (H2O2).[77] In an oxygenated aqueous 
solution, additional hydrogen peroxide may be formed by a route 
involving hydroperoxyl (HO2) radical. We assume that these 
radical species are not scavenged as no additives were added 
during the synthesis. Treatment of GO with Na2S leads to the 
reduction of GO and intercalation of S ions into the carbon 
lattice,[85] yielding S-rGO with a C-S bond acting as a mild 
oxidizer. We assume that S is most probably intercalated in the 
carbon lattice of GO by substitution with oxygen and this 
reaction is enhanced by acoustic cavitation (jets, shock waves, 
capillary waves).[100] Oxidation of unreacted S forms SO3 
followed by SO4 through the nucleophilic reaction between the 
surface OH and epoxy groups of GO.  
In the second step Cu2+ and Fe3+ will react with the S-rGO, 
sulfate ions (adsorbed on GO) and sonochemically formed 
radical species. Metal ions will react with sonochemically 
produced H· (reductant) and a number of oxidizers such as OH·, 
H2O2 and O2· and lead to the oxidation of copper and iron in the 
form of sulfides or oxides (hydroxides). According to the 
oxidation potentials of Cu and Fe,[104] Cu2+ will remain in its 
oxidation state as Cu+ is not stable in the presence of Fe3+. 
According to the standard chemical potentials of Cu and Fe,[105] 
Cu2+ and Fe3+ will react with S and undergo oxidation, yielding 
copper and iron oxides/sulfides and iron hydroxides. The 
structure of CuS can be introduced by trigonal Cu ion bridge 
Cu3S-CuS3 with the disulfide layer (S-S).[85] Oxidation of CuS 
produces sulfates. Pyrite oxidation in alkaline medium (our 
solutions have pH = 10) causes reduction of Fe2+ and formation 
of SO4.[111] Product of pyrite oxidation is Fe3+ oxyhydroxide, i.e. 
goethite α-FeOOH.[115] In addition, ultrasound also causes 
dissolution and hydrolysis of chemical substances,[117] whilst 
oxidation and dissolution reactions are not well-distinguished 
processes.  
In the third step sonochemical reactions proceed with the 
excess amount of a strong reductant (Na2S/Me molar ratio is 
~ 100) meaning that the dominant reaction will be reduction. 
Faster and easier reduction will proceed at higher values of the 
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ferric Fe3+ to ferrous Fe2+ will be faster and more favorable than 
from Cu2+ to Cu+, while formation of metallic compounds (i.e. Fe0 
and Cu0) will proceed very slowly. Sonochemical reduction may 
also lead to the formation of binary compounds such as 
Cu+Fe3+S2 (chalcopyrite) and Cu+Fe2+Fe3+S3 (cubanite), taking 
into account similar system with Ag.[117] Strong reducing 
conditions will lead to the formation of iron hydroxide, which may 
have an intermediate composition between α-FeOOH and α-
Fe2O3 (at pH = 10). Outer hydrous FeOOH may act as a matrix 
for the Fe3+/Fe2+ reactions. In this case possible reaction 
products could be Fe2O3, Fe(OH)2, Cu2S and Cu2O.  
Sonochemical intercalation of ketorolac into 
copper/iron-modified@GO nanocomposites 
We used the anti-inflammatory drug ketorolac in its pristine 
powder form for the sonochemical intercalation into GO 
nanocomposites with the aim to prepare effective nanoscale 
carrier (Figure S4). The molecular drug intercalation into GO 
nanocomposites was examined by Raman microscopy 
(Figure 4).  
Raman spectra reveal characteristic bands of ketorolac 
being in agreement with many NSAIDs[118] and D (1360 cm-1) 
and G (1606 cm-1) main peaks of GO[119] (Figure 4A). Most of 
these Raman peaks from the ketorolac appear in the 
synthesized GO (N1), copper@GO (N2) and copper/iron@GO 
(N7) nanocomposites, but are broader and less defined in 
iron@GO (N9) nanocomposite (Figure 4B and C).  
 
 
Figure 4. (a) Averaged Raman spectra of synthesized GO (black line) and 
bulk microscopic ketorolac powder (Ketorolac, red line); (b) ketorolac being 
intercalated into the synthesized GO (sample N1, red line) and copper@GO 
(sample N2, orange line) nanocomposites; (c) ketorolac being intercalated into 
the copper/iron@GO (sample N7, wine line) and iron@GO (sample N9, violet 
line) nanocomposites. At least five Raman spectra were collected with 10 s of 
integration time for an individual spectrum acquisition at 6x10-3 W laser power 
and 633 nm excitation wavelength. (d) Plot of normalized intensity of 
prominent Raman peak of ketorolac (~ 1328 cm-1) before and after incubation 
of the drug loaded GO nanocomposites in aqueous solution adjusted to one of 
the following pH values: 1, 5 and 8. Experimental data (dots of different 
shapes and color coding) are fitted with the exponential decay curves 
according to the mathematical equations yN1, yN2, yN7 and yN9 with the 
calculated decay constants: 0.6 (sample N7), 0.5 (sample N1), 0.4 (sample 
N2) and 0.1 (sample N9).  
 
Importantly, the prominent Raman peaks from the ketorolac 
at 1328 cm-1 and 1628 cm-1 appear as strong bands in all 
nanocomposites (Figure 4). In each GO nanocomposite the 
intense Raman peak of ketorolac at 1328 cm-1 originates from a 
characteristic band of the γ-amorphous form of ketorolac.[118] 
This prominent Raman peak of ketorolac develops a small 
shoulder closer to the D band of GO, and its stronger 
delocalization illustrates the significant contribution by 
carboxylate groups. This amorphous form of ketorolac may 
contain a range of molecular conformations and intermolecular 
bonding arrangements. Another prominent Raman peak of 
ketorolac at 1628 cm-1 is shifted towards the G band of the GO 
in N1 and N9, but not in N2 and N7, and appears as a shoulder 
in all samples, perturbing the G peak, indicating particular 
binding or complexation mechanisms,[119] which we cannot 
distinguish at the moment (Figure S5).  
Next, we were interested in understanding why explicit 
Raman peaks of ketorolac appear as multiple bands in 
copper/iron@GO than in copper@GO or iron@GO 
nanocomposites. Heretofore the functioning mechanism of 
ketorolac (like many other NSAIDs) is not completely 
understood, but may be related to prostaglandin synthesis 
inhibition.[120] It is accepted that the biological activity of ketorolac 
tromethamine is associated with the S-form having analgesic 
activity. We found a model dye, S-containing methylene blue 
(MB) that is Raman active and has a similar chemical structure 
to the ketorolac that can be used for the sonochemical 
intercalation into GO nanocomposites to reveal the binding 
mechanism of this drug under acoustic field. In contrast to 
ketorolac, Raman spectra show multiple characteristic peaks of 
MB after sonochemical intercalation into copper@GO, 
copper/iron@GO and iron@GO nanocomposites (Figure S6). In 
these spectra strong Raman bands of MB appear at 1326 cm-1 
and 1396 cm-1 being assigned to α(C-H) in-plane ring 
deformation, at 1431 cm-1 and 1441 cm-1 designating νasym(C-N) 
and at 1624 cm-1 demonstrating ν(C-C) ring vibration. These 
Raman bands develop shoulders at 1360 cm-1 and 1606 cm-1 
corresponding to the characteristic Raman D and G bands of 
GO, evidencing successful intercalation of MB into all three 
types of nanocomposites.  
Intense peak at 447 cm-1 is attributed to the δ(C-N-C) 
skeletal bending band of MB, indicating that the molecules were 
adsorbed on the surface of GO nanocomposites.[121] The shifted 
small Raman peak (600 cm-1) designates δ(C-S-C) vibration, 
suggesting that sonochemical intercalation of MB into 
nanocomposites may access via the linkage with S and the 
carbon lattice or via the complexation with CuS or FeS sites 
including interaction with the sulfate groups. Negligible Raman 
peaks positioned at 677 cm-1 and 1039 cm-1 may signify the out-
of-plane bending γ(C-H) and β(C-H), and at 1183 cm-1 may 
specify the stretching ν(C-N) bond of MB, suggesting the in-
plane intercalation of MB into the GO carbon network structure.  
Ketorolac disintegration test in aqueous solutions 
adjusted to pH values from 1 to 8 
For drug delivery application, we examined the drug 
disintegration from the sonochemically prepared GO 
nanocomposite carriers through the detection of a prominent 
Raman peak of ketorolac (1328 cm-1) before and after incubation 
in aqueous solutions adjusted to the following pH values 1, 5 
and 8 (Figure 4D). These pH values were chosen in accordance 
with the pH values of human gastric juice in stomach (~ 1.5-
3.7),[76] lysosomes (~ 4.3-5.3),[77] urine (~ 5.9-6.7),[78] duodenum 
(~ 6.0-8.0),[79] and pancreas or insulin secretion (~ 5.0-10.5).[80] 
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compared to the pristine GO with the aim to find out the 
usefulness of copper, copper/iron or iron compounds in the 
binding to ketorolac. Overall the Raman intensity of ketorolac in 
each GO material monotonically decreases following the 
exponential decay curve if the pH of aqueous solutions was 
increased from 1 to 8. From the values of the peak intensity at 
maximum conditions of the precipitant (Figure 4D), one can 
estimate the peak intensity decay values from the drops of 
supernatant at the studied pH values in terms of the 
approximate amount of the unreacted ketorolac (in mg) after the 
incubation (Table S2). 
However, the rate of Raman intensity decay of ketorolac 
depends on the type of GO nanocomposite over the selected pH 
range. In particular, the decay constant of copper/iron@GO 
nanocomposite is much larger (~ 0.6) than of iron@GO material 
(~ 0.1), suggesting the faster disintegration of ketorolac in 
iron@GO amongst all types of GO nanocarriers starting from 
low pH values. In contrast, ketorolac is still entrapped in 
copper/iron@GO carrier at acidic conditions and slowly 
disintegrates at pH values increased to 8. The disintegration of 
ketorolac from pristine GO and copper@GO is comparable with 
a decay constant being 0.5 and 0.4, suggesting that the 
complexation of ketorolac with copper in the carbon structure of 
GO enriched with oxygen compounds is important for drug 
retaining. This action is strengthened by the presence of both 
copper and iron compounds in sonochemically modified GO 
(sample N7). In addition, at pH = 5 and 8 the surface of GO is 
enriched with COO- groups and GO becomes more hydrophilic, 
while the drug is hydrophobic, meaning that the trapped 
ketorolac in the GO will stay in the fluid flow for extended period 
of time. This finding suggests that ketorolac intercalated into the 
copper/iron@GO nanocomposite may survive aggressive gastric 
medium avoiding harmful action on stomach cells and most 
probably stay in the flow of aqueous medium for the targeted 
delivery.      
Conclusions 
Two feasible sonochemical methods for the formation of 
novel graphene oxide-based nanocomposites and for the 
intercalation of the nonsteroidal anti-inflammatory drug ketorolac 
have been demonstrated here. First, an accessible 
sonochemical method for the modification of graphene oxide 
with copper, copper/iron and iron compounds from graphite has 
been developed using aqueous solution of copper and iron ion 
precursors and ultrasound (20 kHz, 18 W/cm2). Unique 
copper@GO, copper/iron@GO and iron@GO nanocomposites 
acquire a reduced size (< submicron) than pristine GO and a 
higher surface area enriched with Cu2O, CuO, Fe2O3, FeO(OH) 
and sulfur- or carbon-containing compounds. These 
nanocomposites have been examined as potential nanoscale 
carriers for ketorolac entrapment and disintegration in aqueous 
solution. Second, a convenient single-step sonochemical 
method for the intercalation of ketorolac has been developed 
using ultrasound (20 kHz, 8 W/cm2) for 3 min under ambient 
conditions. Ketorolac monotonically disintegrates at a slower 
rate from copper/iron@GO amongst all other nanocomposites 
after incubation in aqueous solution adjusted to a pH from 1 to 8 
due to the more efficient complexation with GO in the presence 
of both copper and iron compounds in the carbon lattice 
structure. Iron@GO has been revealed as the least efficient 
nanocarriers because of the faster ketorolac disintegration at 
acidic conditions. In contrast, ketorolac is still entrapped in the 
copper/iron@GO nanocomposite at low pH and slowly 
disintegrates at increased pH values, meaning that this drug 
may potentially stay in the flow of aqueous medium for extended 
period of time, important for targeted delivery. We believe that 
the developed sonochemical method has a potential to be 
successfully applied to other NSAIDs. 
Experimental Section 
Materials  
Graphite was purchased from IMERYS, France (detailed 
information about the graphite size and elemental composition 
can be found in supporting information). Na2S·9·H2O, 
CuCl2·2·H2O, isopropanol, H3PO4, KMnO4, H2SO4, H2O2 (60%), 
HCl (35%), HNO3 (40%), C2H5OH, FeCl3 6 H2O, methylene blue 
are of higher grade purity 99% being obtained from Belreachim 
JSC (Belarus). Silver nitrate (AgNO3, analytical grade, 99.8 %) 
and sodium borohydride (NaBH4, 98 %) were obtained from 
Sigma-Aldrich Co. (Germany). Distilled water (pH = 5.5, specific 
conductivity 5 S/cm) was prepared by using a homemade 
distillation apparatus (Belarus). We synthesized graphene oxide 
(GO) using the improved Hummers method[122] (more details in 
supporting information). Ketorolac was purchased from Dr. 
Reddy’s Inc. (India). For experiments 10 tablets of ketorolac 
were grinded in a mortar until a fine powder was obtained (more 
details in supporting information). This powder was dissolved in 
3 mL of ethanol at a critical concentration of dissolution being 
7 g/L. Methylene blue solutions were prepared at a 
concentration 1x10-6 mol/L in DI water and filtered through a 
cellulose membrane filter (red line, the pore size 8-12 nm).  
Sonochemical synthesis of copper/iron@graphene 
oxide nanocomposites 
In all our sonochemical experiments we used a homemade 
horn-type ultrasonic disperser N.4-20 operating in a continuous 
mode at 20 kHz frequency with the 400 W maximal output 
power. This ultrasonic disperser was specifically designed by 
Cavitation Inc. (Belarus) for the preparation of emulsions and 
colloidal suspensions. The ultrasonic intensity of this ultrasonic 
device was calibrated by using a method of calorimetry.[123]  
Powder of synthesized GO was dispersed in DI water 
(pH = 5.5) by sonication (18 W/cm2 for 30 min) at a volume ratio 
of powder suspension (0.6 g/L) to water as 1:1 under ambient air 
in the ice bath. As the next step 5 mL of 1 M Na2S aqueous 
solution was added into the sonicated GO suspension. The 
colloidal solution of {Na2S and GO} was sonicated in a sealed 
thermostatic round-bottomed cylindrical container (T = 60°C) for 
1 h at 8 W/cm2 ultrasonic intensity. When sonication was 
finished, this mixture was cooled down to room temperature and 
the powder was precipitated by centrifugation at 4.293,12 x g for 
30 min. The supernatant was removed and the precipitant was 
added by 5 mL of aqueous solution of 10 mM CuCl2 and 5 mL of 
aqueous solution of 10 mM FeCl3 and this mixture was 
sonicated at 18 W/cm2 for 2 h in a sealed thermostatic container 
in the ice bath. Then 5 mL of 1 M Na2S aqueous solution was 
added into the sonicated mixture and ultrasonically treated 
(18 W/cm2 for 1 h) in the ice bath. After that the colloidal 
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and the supernatant was carefully removed. The precipitant was 
dispersed in DI water (pH = 5.5) and washed by centrifugation 
three times until the final pH value of the colloidal dispersion 
reached 5.5. This suspension was dried in the oven at 100°C 
and the fine black powder was obtained.  
In addition, we also performed the synthesis of 
nanocomposites without CuCl2 by taking 10 mL of aqueous 
solution of 10 mM FeCl3, and without FeCl3 at different 
concentration of aqueous solution of CuCl2 (5 mM, 10 mM and 
25 mM) at 0.5 M or 1 M Na2S at a constant volume ratio of 
Na2S:CuCl2 as 1:2. These nanocomposites were designated as 
copper-modified@GO (without Fe) and iron-modified@GO 
(without Cu). All sonochemically prepared surface modified GO 
nanocomposites are designated as follows: a) N1: synthesized 
GO; b) N2: copper-modified@GO; c) N7: copper/iron-
modified@GO and d) N9: iron-modified@GO. 
Intercalation of ketorolac into copper, copper/iron- and 
iron@GO nanocomposites 
3 mg of copper/iron-modified@GO nanocomposites were added 
by 3 mL of freshly prepared solution of ketorolac (at 7 g/L of a 
critical concentration of dissolution in ethanol) and sonicated in 
3 mL of DI water (pH = 5.5) at 8 W/cm2 for 3 min. Then the 
mixture was centrifuged at 4.293,12 x g for 15 min in order to 
remove the unreacted chemical residuals. For Raman 
measurements the ketorolac loaded GO nanocomposites were 
modified with silver as the following. After centrifugation cycles 
the precipitant was added by 3 mL of freshly prepared ice-cold 
aqueous solution of 7 mM NaBH4 and the colloidal suspension 
was sonicated in the ice bath. During first minutes of sonication 
1 mL of fresh 1 mM AgNO3 aqueous solution was dropwise 
added into this colloidal dispersion and ultrasonic treatment was 
immediately stopped. This dispersion was added by 3 mL of 
ketorolac solution followed by 3 min of sonication, removed from 
the ultrasonic reaction vessel and left for one hour at room 
temperature in a dark place. For comparison, we performed 
ultrasonic treatment of colloidal GO dispersions (i.e. N1, N2; N7 
and N9) containing methylene blue dye instead of ketorolac 
(more details in supporting information).  
Drug disintegration test 
1 mL of each colloidal suspension containing surface 
modified GO nanocomposites loaded with ketorolac were 
incubated in 1 mL of DI water adjusted to one of the following pH 
values: 1, 5 and 8. Samples were withdrawn after 7 h, washed 
by repeated centrifugation at 4.293,12 x g for 30 min in order to 
remove the unreacted chemical residuals and diluted with DI 
water. Drops of these aqueous dispersions were placed on glass 
or Al2O3 substrates and left for 8 h of drying at room 
temperature. The presence of intercalated ketorolac was 
examined by its prominent characteristic peak at 1328 cm-1 by 
using Raman microscopy.  
Characterization  
The synthesized nanocomposites were characterized 
through several methods: Dynamic Light scattering (DLS), Zeta 
Potential (ZP), scanning electron microscopy (SEM) and energy 
dispersive X-ray fluorescence (EDX), X-ray powder diffraction 
(XRD), X-ray photoelectron spectroscopy (XPS) and confocal 
Raman microscopy. The size distribution and -potential of 
nanocomposites were measured by DLS from Malvern 
Instruments Ltd. by using a Zetasizer Nano instrument and a 
buffer solution of DI water (pH = 5.5). DLS and -potential 
(electrical charge) experiments were carried out on a 50 times 
diluted colloidal suspension. Each measurement took 10 s; the 
nanoparticle distribution and electrophoretic curves were 
obtained by averaging ten measurements.  
The morphology and elemental composition of 
sonochemically prepared nanocomposites were analyzed and 
characterized by SEM (S-4800) Hitachi, Japan. The phase 
composition was characterized by using powder diffraction 
patterns recorded with an EMPYREAN diffractometer 
(PANalytical, Netherlands) using Cu-Kα radiation (Ni-filter) at 
296 K. X-ray photoelectron spectra (XPS) of our 
nanocomposites were measured by using a custom XPS 
spectrometer equipped with hemispherical electron energy 
analyzer and monochromatized X-Ray AlKα source with 
hν = 1486.6 eV and a spot size of 0.3 mm (SPECS GmBH, 
Germany) in ultra-high vacuum (UHV) conditions. Original XPS 
spectra were corrected for a Shirley background and fitted by 
Gaussian-Lorentzian peak shape (red line) by using the KolXPD 
1.8.0 software developed by scientists in the Charles University 
of Prague, Faculty of Mathematics and Physics/Surface Physics 
(https://www.kolibrik.net/kolxpd).  
Raman spectra were recorded by using a 3D inverted 
confocal Raman microscope Confotec NR500 from SOL 
Instruments Ltd. (Belarusian-Japanese joint venture "SOLAR 
TII") at 633 nm excitation wavelength with a grating 600gr/mm 
blazed at 600 nm. The dried powder, which was modified with 
silver, was placed on a cover slip for laser excitation under 
ambient air. The Si wafer with the characteristic Raman line at 
520 cm-1 was taken as a reference for calibration and basic 
alignment during integration time from 0.3 to 1 s. The acquired 
Raman and SERS spectra were corrected for the baseline and a 
background of the Si wafer. A linearly polarized diode laser 
beam was focused through the objectives with the 100x 
magnification for Raman spectra acquisition. The laser power 
was attenuated by using neutral density filters, which allow the 
transmission of a laser beam with respect to the optical density 
of the filter according to the equation OD=-log(T) with T=I/I0 (I – 
transmitted intensity and I0 – incident laser intensity). The 
following values of OD (T) were used 0.6 (25), 0.3 (50) and no 
filter (100). 
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Supporting Information  
Detailed experimental procedures, characterization of 
synthesized graphene oxide by using DLS, XRD (incl. crystal 
structure database of X-ray powder diffraction files), TGA and 
Raman microscopy, and more XPS spectra fitted by using a 
software KolXPD developed at Charles University (Faculty of 
Mathematics and Physics/Surface Physics, 
https://www.kolibrik.net/kolxpd. This material is available free of 
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